Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN - NTRK2 Fusion.

Competing Interests: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Lawrence W. WuNo relationship to discloseTara PavlockNo relationship to discloseAlison PattersonNo relationship to discloseAnne PostNo relationship to discloseCaitlyn AmbroseNo relationship to discloseVeena RajaramNo relationship to discloseDean C. PavlickEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineMatthew CookeEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation Medicine Travel, Accommodations, Expenses: Foundation MedicineVincent A. MillerEmployment: Foundation Medicine Leadership: Foundation Medicine Stock and Other Ownership Interests: Foundation Medicine Patents, Royalties, Other Intellectual Property: Periodic royalties related to T790M patent awarded to Memorial Sloan Kettering Cancer CenterLee A. AlbackerEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineSiraj M. AliEmployment: Foundation Medicine Leadership: Incyte Stock and Other Ownership Interests: Exelixis, Blueprint Medicines, Agios Pharmaceuticals, Genocea Biosciences Patents, Royalties, Other Intellectual Property: Patents through Foundation Medicine, patents through Seres Therapeutics on microbiome in non-neoplastic disease (I)Steven SmithConsulting or Advisory Role: Loxo OncologyMichael C. CoxEmployment: Bayer AG, Loxo Oncology, Merck, Amgen Stock and Other Ownership Interests: Loxo Oncology, Bayer AG, Merck, Amgen Patents, Royalties, Other Intellectual Property: US patent 62/318,041 issued to Loxo Oncology (Inst)Andrew MartinNo relationship to discloseSteve MegisonNo relationship to discloseTheodore W. LaetschConsulting or Advisory Role: Novartis, Loxo Oncology, Eli Lilly, Bayer AG Research Funding: Pfizer (Inst)